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Background:  Acute myocardial infarction (AMI) induces an inflammatory response leading to heart failure (HF). Galectin-1, a beta-galactoside 
binding lectin, is an immunomodulator that maintains T cell homeostasis and enhances production of interleukin-10. The aim of this study was to 
evaluate the role of Galectin-1 in normal cardiac function and post-AMI ventricular remodeling in mice.
Methods:  Male mice with deletion of the gene encoding Galectin-1 (Lgals1, Gal-1 KO mice) or age and sex matched mice with similar genetic 
background (WT) underwent experimental AMI by surgical ligation of a coronary artery (n=6 for each group). Transthoracic echocardiogram was 
performed at baseline (before surgery) and 7 days after surgery.
Results:  Gal-1 KO mice had a 20% larger left ventricular (LV) end-diastolic diameter (EDD), a 6% greater LV end-systolic diameter (ESD) and a 
20% lower LV fractional shortening (FS), without any difference in body weight. Seven days after AMI both groups showed cardiac enlargement and a 
decrease in cardiac function with Gal-1 KO mice showing a significantly greater increase in LVEDD than WT (see figure).
Conclusion:  Galectin-1 is an innate immune modulator that plays a protective role in normal cardiac homeostasis and in post-
infarction remodeling. Modulation of the immune response using exogenous Galectin-1 may be a viable strategy to prevent HF after AMI.
